News & Events

Entry into a Material Definitive Agreement On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”). The Company will pay interest on the Notes on June 30 and December 30 of each year, beginning on December 30, 2026. The Notes will mature on June 30, 2036. The Notes will be the senior unsecured obligations of the Company and will rank equally with the Company’s other existing and future senior u…

Other Events On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million…

Results of Operations and Financial Condition On April 21, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board’s Compen…

Results of Operations and Financial Condition On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Other Events On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. The 7.5% increase in the quarterly dividend is effective with the dividend payable on April 20, 2026 to shareholders of record of the Company’s common stock on A…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On September 28, 2023, Gail R. Wilensky, Ph.D. informed Quest Diagnostics Incorporated (the “Company”) of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders expected to be held May 2024 (the “2024 Annual Stockholders Meeting”), and to retire from the Board effect…

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with his retirement, Mr. Rusckowski’s existing employment agreement with the company will not be renewed, pursuant to notice given in accordance with the employment agreement on June 29, 2022. Mr. Rusckowski’s compensation for his service as Executive Chairman will generally be aligned with his 2022 compensation .

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. b. Quest Diagnostics Incorporated (the “Company”) announced that Carrie Eglinton Manner, the Company’s Senior Vice President, Advanced and General Diagnostics and Clinical Solutions, resigned from the Company effective June 3, 2022 to join OraSure Technologies, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 24, 2022, Dr. Helen I. Torley informed the Company of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders to be held May 18, 2022 (the “Annual Meeting”). Dr. Torley, who is President and CEO of Halozyme Therapeutics, informed the Company that she desires…

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 24, 2022, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Company approved a special equity grant for Carrie Eglinton Manner, the Company’s Senior Vice President, Advanced Diagnostics, with the purpose of promoting the success of the Company’s management succession plan and to incent Ms. Eglinto…

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 24, 2022, the Compensation Committee of the Board of Directors of the Company approved the following compensation for Mr. Davis for 2022: an annual base salary (“Base Salary”) of $800,000; a target cash incentive compensation award (“Annual Bonus”) of 100% of Base Salary; and a target long-term incentive award (“LTI Award”) for 2022 with…

Other Events In August 2021, ReproSource, a subsidiary of Quest Diagnostics Incorporated, experienced a data security incident in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients. Quest Diagnostics’ systems were not impacted by this incident. In connection with the incident, ReproSource discovered the presence of ransomware, quickly contained the ransomware, and securely restored operations.…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 16, 2021, the Board increased its size from 9 to 10 directors. After considering the recommendation of the Board's Governance Committee, the Board elected Tracey C. Doi, Chief Financial Officer and Group Vice President of Toyota Motor North America, to fill the resulting vacancy, effective immediately. The Board determined that Ms. Do…